A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin’s lymphoma weighing ≤70 kg

A randomized, multicenter, open-label study explored the effect of a fixed-dose (FD) of plerixafor versus the approved weight-based (WB) dose for the mobilization of hematopoietic stem cells (HSCs) in patients with non-Hodgkin’s lymphoma and a body weight of ≤70 kg. After mobilization with granulocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuruvilla, John, Tzeng, Cheng-Hwai, Cho, Seok-Goo, Kim, Seok Jin, Tang, Jih-Luh, Su, Yaming, Wu, Jingyang, Vargo, Rita, Cheverton, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365372/
https://www.ncbi.nlm.nih.gov/pubmed/29895931
http://dx.doi.org/10.1038/s41409-018-0253-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365372/
https://www.ncbi.nlm.nih.gov/pubmed/29895931
http://dx.doi.org/10.1038/s41409-018-0253-y

Ejemplares similares